LENEXA, Kan., May 28, 2025 -- Eurofins Viracor announced today the launch of its new quantitative real-time PCR assays for dimorphic fungi, a significant advancement in the rapid and accurate diagnosis of infections caused by Blastomyces spp., Histoplasma spp., Coccidioides spp., and Cryptococcus (C. gattii and/or C. neoformans). These advanced molecular tests are designed to empower clinicians with timely and reliable diagnostic information, facilitating prompt and targeted treatment for potentially life-threatening fungal infections.
Dimorphic fungal infections pose a considerable challenge in clinical settings, often leading to severe illness and increased patient morbidity and mortality due to factors such as diagnostic delays. Traditional diagnostic methods such as culture, serology, and microscopy can be slow, insensitive, or lack specificity, hindering timely therapeutic intervention, especially in immunocompromised patients or those with acute presentations like meningitis or severe pulmonary disease.
Key benefits of these new assays include:
- Delivers results within hours of sample receipt, crucial for guiding timely treatment.
- PCR from bronchoalveolar lavage (BAL), sputum, or cerebrospinal fluid (CSF), bypasses delays associated with traditional culture methods.
- Facilitates earlier, targeted antifungal therapy, which is essential for reducing morbidity and mortality associated with these infections.
These new assays address a significant unmet need in the clinical microbiology market by leveraging the power of molecular diagnostics to provide fast, highly sensitive, and specific detection of critical fungal pathogens. Eurofins Viracor's commitment to innovation in infectious disease diagnostics is exemplified by this advancement.
For more information about the dimorphic fungal assays and their applications, please visit www.eurofins-viracor.com/our-testing/fungal/ or contact Client Services at (800) 305-5198.
About Eurofins Viracor
With over 40 years of diagnostic expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Eurofins Viracor is passionate about delivering accurate, timely and actionable results, never losing sight of the connection between the testing it performs and the patients it serves.
Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit eurofins.com and eurofins-viracor.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Scientific SE shares are listed on Euronext Paris Stock Exchange.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
